North America Healthcare Devices Market

Overview

The North America healthcare devices market was valued at USD 205.6 billion in 2025 and is projected to reach USD 344.5 billion by 2034, growing at a CAGR of 5.9% during the forecast period (2026-2034). The market is driven by rising chronic disease prevalence, an aging population across the United States and Canada, expanding remote patient monitoring reimbursement, and continued capital investment in hospital and ambulatory diagnostic imaging equipment. The market is shifting from conventional, device-only capital purchases toward software-enabled, continuously updated systems that hospitals license and upgrade over time rather than replace outright. Health systems are increasingly evaluating device vendors on integration with existing electronic health record platforms and total lifecycle service costs rather than upfront purchase price alone. Government initiatives such as the FDA's Quality Management System Regulation (QMSR), which took effect on February 2, 2026 and aligns U.S. device manufacturing requirements with the international ISO 13485:2016 quality standard, are simplifying compliance for companies that already sell into global markets. Complementary USMCA duty-free treatment for compliant North American production is encouraging device makers to expand assembly capacity across the United States, Canada and Mexico rather than source components from outside the region. By Country, The United States accounted for the largest share of the North America healthcare devices market in 2025, supported by extensive hospital infrastructure and established reimbursement pathways. Mexico is projected to be the fastest-growing country market during the forecast period, driven by USMCA-aligned manufacturing investment and expanding public and private hospital capacity across major metropolitan centers.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Artificial Intelligence and Predictive Diagnostics Are Transforming Clinical Workflows Across North America

• Hospitals and diagnostic centers across the United States and Canada are layering artificial intelligence onto existing imaging workstations to flag abnormal scans automatically and prioritize urgent cases. Radiology teams using AI triage software integrated into picture archiving systems report noticeably shorter turnaround times between scan capture and physician review, which improves departmental throughput.
• Device makers are embedding predictive algorithms directly into cardiac monitors, infusion pumps and continuous glucose sensors so clinicians receive early warnings before a patient's condition deteriorates. This shift toward software-defined, continuously updated devices is changing how manufacturers design new products and how hospitals budget for ongoing connected-technology upgrades.
• Interoperability standards from HL7 FHIR and information-blocking rules from the Office of the National Coordinator are pushing device manufacturers to build open data connections instead of closed, proprietary systems. Hospital IT departments increasingly favor vendors whose devices can feed patient data directly into electronic health records without costly custom integration work.
• The FDA selected participants for its TEMPO pilot program in 2026, a streamlined regulatory pathway designed to accelerate premarket review of AI-enabled and other digital health devices developed under evolving software standards.

KEY MARKET DRIVER

Rising Chronic Disease Burden and Home-Based Care Reimbursement Are Driving Market Growth

• The aging population across the United States, Canada and Mexico is increasing demand for devices that manage diabetes, cardiovascular disease and respiratory conditions over long periods rather than during single hospital visits. Physicians are prescribing connected monitoring devices earlier in the disease course to help reduce costly emergency admissions.
• Health systems are shifting more diagnostic and therapeutic procedures out of hospitals and into ambulatory surgical centers and patients' homes to control costs and free up inpatient capacity. This transition is expanding demand for portable ultrasound units, wearable cardiac monitors and home dialysis equipment across the region.
• Private insurers are following Medicare's lead by expanding coverage for remote patient monitoring services, giving device manufacturers a clearer commercial pathway for connected blood pressure cuffs, glucose sensors and pulse oximeters. Clinics are investing in monitoring hardware because reimbursement now offsets a meaningful share of the equipment cost.
• The Centers for Medicare and Medicaid Services lowered the clinical staff time required to bill remote patient monitoring and remote therapeutic monitoring services starting in 2026, letting providers qualify for reimbursement with as little as ten minutes of monthly treatment management.

KEY MARKET OPPORTUNITY

USMCA-Aligned Manufacturing and Nearshoring Are Opening New Investment Pathways

• Tariff exposure on devices imported from outside North America is prompting manufacturers to qualify more of their component sourcing under USMCA rules of origin so finished products can enter the United States duty-free. Contract manufacturers in Mexico are positioned to capture new assembly work as companies restructure their supply chains.
• Domestic capacity expansion is creating an opening for smaller contract manufacturers and component suppliers to win multi-year supply agreements with larger device makers seeking to document North American origin for every input. Facilities that can prove USMCA compliance are becoming more attractive acquisition targets for private equity buyers.
• Growing procedure volumes in ambulatory surgical centers are creating room for mid-sized manufacturers to sell directly into a channel that historically favored the largest device makers with hospital-wide purchasing contracts. Smaller, specialized device companies are using this shift to gain shelf space without competing head-on for hospital system tenders.
• The U.S. Department of Commerce opened a Section 232 national security investigation into medical device imports in September 2025, a proceeding that could reshape tariff treatment for non-USMCA-compliant products and remained under review as of mid-2026. Filing details are available on the Federal Register's Section 232 device investigation docket.

North America Healthcare Devices Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Diagnostic and imaging devices held the largest share of the North America healthcare devices market in 2025, supported by the region's dense installed base of MRI, CT, ultrasound and X-ray systems across hospitals, imaging centers and outpatient clinics. Routine cancer screening programs, an aging population requiring more frequent diagnostic workups, and steady replacement cycles for aging hospital imaging fleets keep utilization high throughout the year. Radiology departments are also upgrading toward digital and AI-assisted platforms rather than replacing equipment on a like-for-like basis, which sustains average selling prices even as unit volumes grow only moderately. Well-established reimbursement codes for imaging procedures under Medicare and private insurance further support consistent capital spending on this equipment category across the United States and Canada.

Diabetes care devices are projected to grow at the fastest pace among product categories during the forecast period, driven by rising diabetes prevalence across the United States and growing physician comfort prescribing continuous glucose monitors to patients earlier in their treatment journey. Insurance coverage for continuous glucose monitoring has broadened in recent years, extending access beyond insulin-dependent patients to a wider population managing Type 2 diabetes through diet and oral medication. Manufacturers are also integrating glucose sensors with automated insulin delivery systems, creating closed-loop products that reduce the daily burden of manual dosing and appeal to both patients and prescribing physicians. Continued clinical evidence linking continuous monitoring to better glycemic control is expected to keep this category ahead of other device types through 2034.

Product Type categories include

• Diagnostic & Imaging Devices (Dominating Segment)
• Diabetes Care Devices (Highest CAGR Segment)
• Cardiovascular Devices
• Orthopedic Devices
• In Vitro Diagnostic (IVD) Devices

Analysis by Technology

Conventional and manual devices held the largest share of the market because the region's enormous installed base of surgical instruments, manual monitoring equipment and non-connected diagnostic tools remains in daily clinical use across thousands of hospitals and clinics. Replacement of this equipment happens gradually, since much of it is durable, inexpensive relative to connected alternatives, and does not require the cybersecurity review or IT integration that digital devices demand before hospital procurement teams approve purchases. Smaller clinics and rural facilities in particular continue to rely on manual equipment because of lower upfront costs and simpler maintenance requirements. This broad, entrenched usage base keeps conventional devices dominant even as digital adoption accelerates in larger health systems.

AI-enabled devices are projected to grow at the fastest CAGR during the forecast period as hospitals move beyond pilot programs and begin embedding machine learning directly into diagnostic imaging, patient monitoring and surgical navigation equipment. Regulatory clarity is improving as the FDA works through an expanding pipeline of AI-enabled device submissions and pilots streamlined review pathways for software that continues learning after initial clearance. Large health systems are prioritizing AI-enabled purchases because these tools can reduce radiologist workload, flag deteriorating patients earlier on hospital wards, and support staff during a period of persistent clinical labor shortages across North America. As more AI models demonstrate measurable outcome improvements in peer-reviewed studies, hospital technology committees are approving these products at a faster rate than in prior years.

Technology categories include

• Conventional & Manual Devices (Dominating Segment)
• AI-Enabled Devices (Highest CAGR Segment)
• Connected & IoT-Enabled Devices
• Robotic-Assisted Devices
• Wearable Devices

Analysis by End User

Hospitals held for the largest share of the because they perform the highest volume of complex diagnostic, surgical and monitoring procedures that require capital equipment unavailable in smaller care settings. Large health systems also negotiate group purchasing contracts that give them access to the newest device generations soon after regulatory clearance, keeping their equipment current and driving repeat capital spending. Trauma centers, cardiac catheterization labs and operating rooms all depend on continuous device investment to maintain accreditation and meet patient safety standards set by hospital regulators. This scale and complexity of care keep hospitals as the anchor purchasing channel for device manufacturers across the region.

Homecare settings are projected to grow at the fastest CAGR during the forecast period as health systems discharge patients earlier and rely on connected devices to monitor recovery remotely rather than keeping patients in costly inpatient beds. Congress extended the CMS Acute Hospital Care at Home waiver for five years in 2026, giving hospitals long-term policy certainty to continue building programs that deliver hospital-level care inside a patient's residence using remote monitoring equipment. Expanded Medicare reimbursement for remote patient monitoring is giving device makers a clearer commercial case for selling directly into the home care channel rather than only through hospital procurement departments. As more health systems formalize hospital-at-home programs, demand for portable vital-sign monitors, infusion equipment and telehealth-connected devices is expected to keep outpacing growth in traditional care settings.

End User categories include

• Hospitals (Dominating Segment)
• Homecare Settings (Highest CAGR Segment)
• Ambulatory Surgical Centers
• Clinics
• Diagnostic & Imaging Centers

Analysis by Distribution Channel

Direct and institutional tenders held the largest share of the market because large hospital systems and group purchasing organizations negotiate multi-year supply agreements directly with device manufacturers for capital equipment and recurring consumables. These contracts give hospitals predictable pricing and give manufacturers stable, high-volume revenue, which is why most major device makers maintain dedicated institutional sales teams focused on health system accounts rather than smaller distributors. Government hospitals and academic medical centers, which represent a meaningful share of procurement volume in the United States and Canada, are required to run formal tendering processes that favor manufacturers with established direct relationships. This structural preference for direct engagement keeps institutional tenders the primary channel through which most device revenue flows.

E-commerce channels are projected to grow at the fastest CAGR during the forecast period as smaller clinics, home health agencies and individual patients increasingly purchase lower-risk devices such as pulse oximeters, blood pressure monitors and glucose meters directly online rather than through traditional medical distributors. Manufacturers are building direct-to-consumer web storefronts alongside their institutional sales operations to capture this growing segment of buyers who want faster delivery and transparent pricing. The expansion of home-based care and remote patient monitoring programs is reinforcing this trend, since patients and caregivers often need to purchase or replace connected devices without going through a hospital's procurement department. This channel remains small relative to institutional tenders but is expanding quickly as digital health adoption broadens.

Distribution Channel categories include

• Direct & Institutional Tenders (Dominating Segment)
• E-Commerce Channels (Highest CAGR Segment)
• Third-Party Distributors
• Retail Pharmacies 

By Region

North America Healthcare Devices Market Share, 2025 (CAGR)

North America

xx%

South America

xx%

Europe

xx%

Middle East Africa

xx%

Asia Pacific

xx%

The United States is the dominant healthcare devices market within North America, supported by more than 6,000 hospitals, extensive ambulatory surgical center networks, and a Medicare and private insurance system that reliably reimburses both inpatient and outpatient device-based procedures. The FDA's Center for Devices and Radiological Health processes the majority of new device clearances used across the region, giving American providers first access to newly approved technologies. Ongoing tariff and Section 232 trade policy developments are prompting device manufacturers to reassess sourcing, with several companies publicly disclosing meaningful tariff-related cost exposure in 2025 and 2026. Group purchasing organizations continue to consolidate hospital buying power, giving large device makers a predictable, high-volume commercial channel across most U.S. states.

Mexico is the fastest-growing country market in North America's healthcare devices industry, benefiting from its role as a USMCA-compliant manufacturing base for device makers seeking to avoid tariffs applied to non-compliant imports from outside the region. Public investment in expanding IMSS and Secretaria de Salud facilities is gradually increasing demand for diagnostic and monitoring equipment outside major metropolitan areas. Multinational manufacturers are expanding assembly and component operations in border states such as Baja California and Chihuahua, which strengthens the domestic supply base while also creating new commercial relationships with Mexican distributors. Growing private hospital networks in cities including Mexico City, Guadalajara and Monterrey are additional demand centers for advanced diagnostic and surgical equipment.

Countries Covered

• United States (Largest Country Market)
• Canada
• Mexico (Fastest-Growing Country Market)

Market Share

The North America healthcare devices market is consolidated, with a small number of large diversified manufacturers such as Medtronic, Abbott, Stryker, Boston Scientific and Johnson & Johnson MedTech accounting for a substantial share of regional revenue through broad, multi-category product portfolios and deep hospital purchasing relationships. Alongside these diversified leaders, a large number of specialized manufacturers compete in narrower categories such as diabetes care, orthopedics and diagnostic imaging, adding meaningful fragmentation beneath the top tier. Key success factors include regulatory clearance speed, clinical evidence generation and the ability to secure group purchasing organization contracts with major U.S. health systems. Leading companies are prioritizing bolt-on acquisitions in cardiovascular and neurovascular technology, AI-enabled software integration, and supply chain restructuring to manage tariff exposure under the current U.S. trade policy environment.

Key Players

• Medtronic plc (Ireland)
• Abbott Laboratories (United States)
• Stryker Corporation (United States)
• Boston Scientific Corporation (United States)
• Johnson & Johnson (United States)
• Becton, Dickinson and Company (United States)
• GE HealthCare Technologies Inc. (United States)
• Baxter International Inc. (United States)
• Zimmer Biomet Holdings, Inc. (United States)
• Edwards Lifesciences Corporation (United States)
• Intuitive Surgical, Inc. (United States)
• ResMed Inc. (United States)
• DexCom, Inc. (United States)
• Insulet Corporation (United States)
• Hologic, Inc. (United States)
• Solventum Corporation (United States)
• Siemens Healthineers AG (Germany)
• Masimo Corporation (United States)
• Teleflex Incorporated (United States)
• Integra LifeSciences Holdings Corporation (United States)

Recent Market Developments

• In December 2025, Hologic, Inc. entered into a definitive agreement to be acquired by Blackstone and TPG in a transaction with an enterprise value of up to USD 18.3 billion, one of the largest healthcare take-private deals of the year; the diagnostics maker's headquarters is set to remain in Marlborough, Massachusetts, and the deal strengthens private-capital investment in North American diagnostics manufacturing.
• In January 2026, Boston Scientific Corporation announced a USD 14.5 billion agreement to acquire Penumbra, Inc., expanding its neurovascular and interventional thrombectomy portfolio and reinforcing its position in stroke and clot-removal technology sold to hospitals across the United States and Canada.
• In April 2026, Stryker Corporation closed its acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform that strengthens its peripheral vascular portfolio alongside its existing Inari Medical clot-removal business, expanding the interventional options Stryker offers to North American vascular surgeons.
• In April 2026, Abbott received U.S. FDA clearance for its next-generation Ultreon 3.0 Software, an AI-powered optical coherence tomography platform that gives physicians real-time guidance during percutaneous coronary intervention procedures performed in U.S. cardiac catheterization labs.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is the North America Healthcare Devices Market?

2

What is the CAGR of the North America Healthcare Devices Market?

3

Which product type leads the North America Healthcare Devices Market?

4

Which product type is growing the fastest in the North America Healthcare Devices Market?

5

Which end user dominates the North America Healthcare Devices Market?

6

Which country dominates the North America Healthcare Devices Market?

7

What are the latest trends in the North America Healthcare Devices Market?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates